Articles related to CLINICAL TRIALS

In a recent phase 3 trial, alectinib has shown a notable improvement in both disease-free and CNS disease-free survival in patients with ALK-positive NSCLC, indicating a robust alternative to platinum-based chemotherapy regimens.

This study sheds light on lixisenatide’s potential in Parkinson’s disease, showing a notable slowing of motor disability progression, although accompanied by gastrointestinal side effects, underlining the importance of further research to validate these findings.

This study introduces a pivotal model that aids physicians in making informed decisions regarding bone marrow sampling for MGUS patients, utilizing a comprehensive set of biomarkers to predict the progression to SMM or worse conditions with high accuracy.

Explore this development in metastatic melanoma treatment with the FDA’s accelerated approval of TIL therapy, a promising approach for patients who have exhausted other options.

In a recent phase 2–3 trial, nirmatrelvir–ritonavir did not significantly shorten the time to COVID-19 symptom resolution compared to placebo, yet it demonstrated a trend towards reduced hospitalization and death rates, emphasizing the importance of tailored treatment strategies.

Imetelstat has shown promising results in improving the quality of life for MDS patients by significantly reducing transfusion dependency, a critical consideration in the management of this blood disorder.